ESMO

Radiotherapy Should Be Added to Hormone Therapy in Node-Positive Prostate Cancer as the New Standard of Care

In the normal course of events node-positive prostate cancer has typically been excluded from clinical trials. This leaves our oncologists with little evidence to guide the management for those of us who have this flavor of prostate cancer. A recent anaylisis presented at the European Society for Medical Oncology (ESMO) 2014 Congress begins to shed [...]

By Malecare|2020-02-04T10:48:26-05:00November 13th, 2014|ADT, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ESMO, Uncategorized, Understanding APC|0 Comments

Updated Overall Survival (OS) Data from a Phase 3 Trial of Ipilimumab (Ipi) vs. Placebo in Men Post Chemotherapy

In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]

By Malecare|2017-10-19T10:47:45-04:00October 23rd, 2014|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, ESMO, immunotherapy, ipilimumab, Radiotherapy, Uncategorized, vaccines|0 Comments